Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Aims and methods: The aim of this monocentric retrospective observational study was to evaluate the 18-month safety and effectiveness of GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) 1.5 mg/once weekly as an add-on to metformin (MET) or MET plus conventional insulin secretagogues in a study coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirabelli, Maria, Chiefari, Eusebio, Tocci, Vera, Caroleo, Patrizia, Giuliano, Stefania, Greco, Emanuela, Luque, Raul Miguel, Puccio, Luigi, Foti, Daniela Patrizia, Aversa, Antonio, Brunetti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957905/
https://www.ncbi.nlm.nih.gov/pubmed/33801192
http://dx.doi.org/10.3390/jcm10050985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957905/
https://www.ncbi.nlm.nih.gov/pubmed/33801192
http://dx.doi.org/10.3390/jcm10050985

Ejemplares similares